신경퇴행성 질환 시장 보고서(2026년)

Neurodegenerative disease refers to a category of disorders marked by the gradual deterioration of the structure and function of the nervous system, including the brain and spinal cord. This field focuses on understanding, diagnosing, and treating these conditions through advances in biotechnology, pharmaceuticals, and medical technologies. Its objectives include slowing disease progression, improving patient outcomes, and lowering the overall healthcare burden. It plays a key role in supporting aging populations, advancing neurological care, and promoting a sustainable, technology-driven healthcare system.

The major types of neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Parkinson's disease is a progressive neurological condition that impairs movement control due to the loss of dopamine-producing neurons in the brain. These disorders are managed using various drug classes, such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory agents. Routes of administration include oral, injectable, transdermal, and other methods. These medications are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution outlets. The primary end users include hospitals, retail providers, and online platforms.

Tariffs have affected the neurodegenerative disease market by increasing costs for imported active pharmaceutical ingredients, advanced diagnostic devices, and biotechnological equipment. Segments such as injectable therapies, gene-based treatments, and specialized diagnostic tools are particularly impacted, with regions like Europe, North America, and Asia-Pacific facing supply chain and price pressures. However, tariffs have also encouraged local manufacturing, domestic r&d investments, and the development of cost-efficient therapies, supporting long-term market resilience.

The neurodegenerative disease market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disease market statistics, including neurodegenerative disease industry global market size, regional shares, competitors with a neurodegenerative disease market share, detailed neurodegenerative disease market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disease industry. This neurodegenerative disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurodegenerative disease market size has grown strongly in recent years. It will grow from $57.23 billion in 2025 to $62.59 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to limited understanding of disease pathology, reliance on conventional symptomatic treatments, growing aging population, increasing healthcare infrastructure for neurology, limited availability of advanced diagnostic tools.

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $88.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to advancements in gene and cell therapy, rising r&d in novel neuroprotective drugs, expansion of clinical trial networks, integration of ai for early diagnosis and patient monitoring, increasing adoption of personalized medicine approaches. Major trends in the forecast period include rising prevalence of neurodegenerative disorders, increasing investment in drug development and clinical trials, adoption of targeted and personalized therapies, growth in awareness and early diagnosis programs, expansion of home-based and outpatient care solutions.

The growing level of research activity and the rising number of clinical trials are expected to drive the growth of the neurodegenerative disease market in the coming years. Clinical trials are research investigations involving human participants that assess the safety, effectiveness, and potential side effects of new therapies, drugs, or medical devices. The increase in research and clinical trials is mainly driven by the expanding need for novel treatments to address evolving healthcare demands and improve patient outcomes. Clinical trials play a vital role in neurodegenerative disease research by generating essential evidence on the safety and efficacy of emerging therapies, thereby supporting therapeutic advancement and enhancing patient care. For instance, in December 2024, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based industry body, the number of UK industry-sponsored clinical trials initiated increased by 3.7% in 2023 compared to 2022. Therefore, the rise in research and clinical trials is contributing to the growth of the neurodegenerative disease market.

Major companies operating in the neurodegenerative disease market are concentrating on the development of innovative solutions, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, to improve treatment accuracy, enhance disease-modifying potential, and elevate patient quality of life. Next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation technologies designed to deliver real-time, personalized therapy for Parkinson's disease by continuously adjusting stimulation settings based on neural feedback, thereby optimizing therapeutic benefits and reducing side effects. For instance, in February 2025, Medtronic, a US-based medical technology company, obtained approval from the U.S. Food and Drug Administration (USFDA) for the world's first adaptive deep brain stimulation (aDBS) system for Parkinson's disease. This approval relates to the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically modifies therapy in response to a patient's brain signals. The system is clinically validated to provide symptom relief for patients with advanced Parkinson's disease and represents a major advancement in personalized neuromodulation treatments.

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie aims to accelerate the development of potentially disease-modifying therapies for Alzheimer's disease and reinforce its neuroscience pipeline by utilizing Aliada's innovative drug delivery platform capable of crossing the blood-brain barrier. Aliada Therapeutics is a US-based company focused on developing precision medicines for neurological disorders.

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurodegenerative disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disease Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neurodegenerative disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurodegenerative disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Amyotrophic Lateral Sclerosis
• 2) By Drug Type: N-methyl-D-aspartate Receptor antagonists; Cholinesterase Inhibitors; Dopamine Agonists; Immunomodulatory Drugs; Acetylcholinesterase (AChE) Inhibitors; Antagonist; Monoamine Oxidase B (MAO-B) Inhibitor; Catechol-O-Methyltransferase (COMT) Inhibitor; Selective Serotonin Reuptake Inhibitor (SSRIs); Other Drug Types
• 3) By Route of Administration: Oral; Injectable; Transdermal; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospital; Retail; Online
• Subsegments:
• 1) By Parkinson's Disease: Idiopathic Parkinson's Disease; Familial Parkinson's Disease; Early-Onset Parkinson's Disease; Parkinsonism
• 2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease; Late-Onset Alzheimer's Disease; Familial Alzheimer's Disease (FAD); Inflammatory Subtype; Non-Inflammatory Subtype; Cortical Subtype
• 3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS); Relapsing-Remitting MS (RRMS); Secondary Progressive MS (SPMS); Primary Progressive MS (PPMS); Progressive-Relapsing MS (PRMS)
• 4) By Huntington's Disease: Adult-Onset Huntington's Disease; Juvenile Huntington's Disease
• 5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS; Limb-Onset ALS; Bulbar-Onset ALS; Respiratory-Onset ALS; Primary Lateral Sclerosis (PLS); Progressive Muscular Atrophy (PMA); Juvenile ALS; ALS-Parkinsonism-Dementia Complex (ALS-PDC)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Sanofi S.A.; Novartis AG; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Merck & Co. Inc.; Biogen Inc.; Neurocrine Biosciences Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Cassava Sciences Inc.; Denali Therapeutics Inc.; Voyager Therapeutics Inc.; AC Immune SA; Amylyx Pharmaceuticals Inc.; Sage Therapeutics Inc.; Alzheon Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Neurodegenerative Disease Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Neurodegenerative Disease Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Neurodegenerative Disease Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Neurodegenerative Disease Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Immersive Technologies (Ar/Vr/Xr) & Digital Experiences
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Neurodegenerative Disorders
  • 4.2.2 Increasing Investment In Drug Development And Clinical Trials
  • 4.2.3 Adoption Of Targeted And Personalized Therapies
  • 4.2.4 Growth In Awareness And Early Diagnosis Programs
  • 4.2.5 Expansion Of Home-Based And Outpatient Care Solutions

5. Neurodegenerative Disease Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Neurology Clinics
• 5.3 Pharmaceutical And Biotechnology Companies
• 5.4 Research Institutions
• 5.5 Home Healthcare Providers

6. Neurodegenerative Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neurodegenerative Disease Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Neurodegenerative Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Neurodegenerative Disease Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Neurodegenerative Disease Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Neurodegenerative Disease Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neurodegenerative Disease Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neurodegenerative Disease Market Segmentation

• 9.1. Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
• 9.2. Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
• 9.3. Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Transdermal, Other Routes Of Administration
• 9.4. Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
• 9.5. Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Retail, Online
• 9.6. Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-Onset Parkinson's Disease, Parkinsonism
• 9.7. Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Early-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease, Familial Alzheimer's Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
• 9.8. Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
• 9.9. Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adult-Onset Huntington's Disease, Juvenile Huntington's Disease
• 9.10. Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

10. Neurodegenerative Disease Market Regional And Country Analysis

• 10.1. Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neurodegenerative Disease Market

• 11.1. Asia-Pacific Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neurodegenerative Disease Market

• 12.1. China Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neurodegenerative Disease Market

• 13.1. India Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neurodegenerative Disease Market

• 14.1. Japan Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neurodegenerative Disease Market

• 15.1. Australia Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neurodegenerative Disease Market

• 16.1. Indonesia Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neurodegenerative Disease Market

• 17.1. South Korea Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neurodegenerative Disease Market

• 18.1. Taiwan Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neurodegenerative Disease Market

• 19.1. South East Asia Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neurodegenerative Disease Market

• 20.1. Western Europe Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neurodegenerative Disease Market

• 21.1. UK Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neurodegenerative Disease Market

• 22.1. Germany Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neurodegenerative Disease Market

• 23.1. France Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neurodegenerative Disease Market

• 24.1. Italy Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neurodegenerative Disease Market

• 25.1. Spain Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neurodegenerative Disease Market

• 26.1. Eastern Europe Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neurodegenerative Disease Market

• 27.1. Russia Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neurodegenerative Disease Market

• 28.1. North America Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neurodegenerative Disease Market

• 29.1. USA Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neurodegenerative Disease Market

• 30.1. Canada Neurodegenerative Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neurodegenerative Disease Market

• 31.1. South America Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neurodegenerative Disease Market

• 32.1. Brazil Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neurodegenerative Disease Market

• 33.1. Middle East Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neurodegenerative Disease Market

• 34.1. Africa Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Neurodegenerative Disease Market, Segmentation By Disease Type, Segmentation By Drug Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neurodegenerative Disease Market Regulatory and Investment Landscape

36. Neurodegenerative Disease Market Competitive Landscape And Company Profiles

• 36.1. Neurodegenerative Disease Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Neurodegenerative Disease Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Neurodegenerative Disease Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Neurodegenerative Disease Market Other Major And Innovative Companies

• Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

38. Global Neurodegenerative Disease Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neurodegenerative Disease Market

40. Neurodegenerative Disease Market High Potential Countries, Segments and Strategies

• 40.1 Neurodegenerative Disease Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Neurodegenerative Disease Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Neurodegenerative Disease Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer